Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors

Cancer

Volumn 113, Issue 11, 2008, Pages 3130-3136

  Bilimoria, Karl Y ^a,b   Shen, Wen T ^b   Elaraj, Dina ^a   Bentrem, David J ^a   Winchester, David J ^a,d   Kebebew, Electron ^c   Sturgeon, Cord ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b AMERICAN COLLEGE OF SURGEONS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Evanston Northwestern Healthcare ^*  (United States)

Author keywords

Adrenocortical carcinoma; Chemotherapy; National cancer data base; Prognostic factors; Surgery; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR VOLUME; UNITED STATES;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 56649085323     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23886     Document Type: Article

References (24)

1. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12:667-680.
2. Gonzalez RJ, Tamm EP, Ng C, et al. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery. 2007;142:867-875.
3. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25:891-897.
4. Paton BL, Novitsky YW, Zerey M, et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery. 2006;140:914-920; discussion 919-920.
5. Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg. 2001;136:543-549.
6. Phan AT. Adrenal cortical carcinoma-review of current knowledge and treatment practices. Hematol Oncol Clin North Am. 2007;21:489-507; viii-ix.
7. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91:2027-2037.
8. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg. 2001;25:914-926.
9. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372-2380.
10. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719-726.
11. Jensen JC, Pass HI, Sindelar WF, Norton JA. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg. 1991;126:457-461.
12. Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872-878.
13. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683-690.
14. International Classification of Disease for Oncology. 2nd ed. Geneva, Switzerland: World Health Organization; 1990.
15. International Classification of Disease for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
16. Standards of the Commission on Cancer Volume II: Registry Operations and Data Standards. Vol.II. Chicago: Commission on Cancer; 1998.
17. Facility Oncology Registry Data Standards. Chicago: Commission on Cancer; 2004.
18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Cox D. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
20. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer. 1998;83:2194-2200.
21. Decker RA, Elson P, Hogan TF, et al. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery. 1991;110:1006-1013.
22. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery. 112:963-970, 1992; discussion 970-971.
23. Kirschner LS. Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab. 2006;91:14-21.
24. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8:163-169.